Latest news about Dipna Pharmachem
Dipna Pharmachem
5.78
-0.04(-0.69%)
Company Performance:
View Company Insights1D-0.69%
1M-21.15%
6M-54.67%
1Y-76.56%
5Y-78.94%
More news about Dipna Pharmachem
25May 26
Dipna Pharmachem Approves Secretarial Auditor FY 2025-26
Dipna Pharmachem Limited has successfully concluded its postal ballot process for the appointment of M/s. Jay Pandya & Associates as Secretarial Auditor for the financial year 2025-26. The resolution received strong shareholder approval, with 99.77% of valid votes cast in favour. The e-voting process was conducted from April 23, 2026, to May 22, 2026, in compliance with SEBI regulations.
22Apr 26
Dipna Pharmachem Postal Ballot for Secretarial Auditor Appointment FY 2025-26
Dipna Pharmachem Limited announced a postal ballot notice for appointing M/s. Jay Pandya & Associates as Secretarial Auditor for FY 2025-26, following board approval on April 22, 2026. The appointment requires shareholder approval through remote e-voting from April 23 to May 22, 2026, with results to be announced by May 26, 2026. The firm holds FRN S2024GJ963300 and Peer Review Certificate No. 7830/2026.
15Apr 26
Dipna Pharmachem Limited Submits SEBI Compliance Certificate for Q4FY26
Dipna Pharmachem Limited submitted its quarterly SEBI compliance certificate for Q4FY26, confirming no dematerialization activities occurred during the quarter ended March 31, 2026. The certificate, issued by RTA Bigshare Services Private Limited, was submitted to BSE on April 15, 2026, demonstrating the company's adherence to regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018.
08Apr 26
Dipna Pharmachem Limited Clarifies Significant Price Movement to BSE
Dipna Pharmachem Limited responded to BSE's inquiry about significant share price movement on April 7, 2026, clarifying that no material or price-sensitive information from the company caused the volatility. The company confirmed compliance with all SEBI disclosure requirements and attributed the price movement to natural market forces rather than company-specific events.
21Jan 26
Dipna Pharmachem Limited Receives BSE Trading Approval for 22.44 Lakh Equity Shares from Warrant Conversion
Dipna Pharmachem Limited received BSE trading approval for 22,44,000 equity shares issued through warrant conversion on preferential basis, effective January 20, 2026. The shares, priced at ₹13.05 each (₹10.00 face value plus ₹3.05 premium), were allotted to non-promoters with total value of approximately ₹29.27 crores. The approval process began with warrant application in March 2025 and culminated with trading commencement following proper regulatory compliance under SEBI regulations.
21Jan 26
Dipna Pharmachem Responds to BSE Inquiry on Stock Price Movement, Cites Market-Driven Volatility
Dipna Pharmachem Limited responded to BSE's inquiry about significant stock price movement on January 21, 2026, clarifying that no price-sensitive information exists within the company. The firm confirmed compliance with SEBI LODR Regulations 2015 and attributed the price volatility to natural market forces rather than company-specific developments.
26Nov 25
Dipna Pharmachem Reports 319% Surge in Net Profit for H1 FY2026, Raises Funds Through Convertible Warrants
Dipna Pharmachem Limited, a pharmaceutical trading company, reported a 319% increase in net profit to Rs 141.10 lakhs for H1 FY2026, despite an 18.85% decrease in total income to Rs 7,354.12 lakhs. The company raised Rs 1,893.31 lakhs through convertible warrants in September 2025. Dipna Pharmachem confirmed no deviations in fund utilization from its rights and preferential issues. Historical data shows fluctuating revenue but improving profitability trends since FY2021.
09Sept 25
Dipna Pharmachem Allots 2.99 Crore Convertible Warrants at Rs 13.05 Each on Preferential Basis
Dipna Pharmachem Limited has approved the issuance of 2,98,74,000 convertible warrants at Rs 13.05 per warrant on a preferential basis to promoter and non-promoter categories. Each warrant is convertible into one equity share within 18 months of allotment. The company has collected 25% of the total consideration, amounting to Rs 9,74,63,925.00. The warrants were allotted to 23 individuals and entities, with Keyur Dipakkumar Shah and Ashok Dilipkumar Jain receiving the largest allocations.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Dr Reddys Laboratories
Aurobindo Pharma
Laurus Labs
1,912.70
(-1.18%)
6,794.00
(-0.61%)
4,936.10
(+0.71%)
1,422.40
(-1.18%)
1,133.90
(-1.47%)
2,490.10
(-0.25%)
2,507.20
(-0.71%)
1,228.40
(-1.28%)
1,543.20
(-1.37%)
1,531.40
(-0.42%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
